The official story ("And we're sticking to it") is that this is a Myrexis invention and EpiCept gets those payments for work done for hire. I wasn't watching when all this happened. Doesn't really make sense, but you wouldn't expect new documents to be written in a way that contradicts the official version.
Note that contracting out candidate discovery and pre-clinical evaluation is the stated mode of operation for Myrexis post-layoffs. So they seem to be drinking the Kool-Ade.
You're alluding to inside details that suggest you've been closer to the action, jacosa. Is there more to your story?
Anywho, it's odd, all those diverse researchers in the patent and where is Murray and Sandy? EpiCept may have wiped their hands of Azixa (though I see no such declaration)as they are pursuing an unrelated but similar acting "crolibulin" in P2 against thyroid cancer:
I know NOTHING more. My only reference to inside details was to say that I don't know them, and to imply that somebody who had been following Myriad for a longer time might know more. The official story that Azixa is an in-house discovery is repeated frequently. That rather flies in the face of the payments made to EpiCept, and the only way I can see to reconcile the two is the 'work for hire' story.